City Therapeutics (NASDAQ:CTY) Shares Up 11.6% – What’s Next?

Shares of City Therapeutics, Inc. (NASDAQ:CTY) traded up 11.6% on Thursday. The stock traded as high as $18.99 and last traded at $18.99. 21,912 shares traded hands during mid-day trading, a decline of 92% from the average session volume of 271,121 shares. The stock had previously closed at $17.01.

Analyst Upgrades and Downgrades

CTY has been the topic of a number of research analyst reports. Jefferies Financial Group initiated coverage on shares of City Therapeutics in a report on Tuesday. They issued a “buy” rating and a $32.00 price target on the stock. Wall Street Zen upgraded shares of City Therapeutics to a “hold” rating in a research report on Saturday, October 24th. Stifel Nicolaus started coverage on City Therapeutics in a research note on Tuesday. They issued a “buy” rating and a $34.00 target price on the stock. Finally, Oppenheimer assumed coverage on City Therapeutics in a research report on Tuesday. They set an “outperform” rating and a $46.00 price target on the stock. Three equities research analysts have rated the stock with a Buy rating. Based on data from MarketBeat.com, City Therapeutics presently has an average rating of “Buy” and a consensus target price of $37.33.

City Therapeutics Trading Up 10.7%

Insider Transactions at City Therapeutics

In other news, major shareholder Arch Venture Partners Xii, Llc bought 170,000 shares of the company’s stock in a transaction dated Monday, October 19th. The stock was bought at an average cost of $18.00 per share, for a total transaction of $3,060,000.00. Following the completion of the acquisition, the insider owned 13,692,507 shares in the company, valued at approximately $246,465,126. This trade represents a 1.26% increase in their position. The acquisition was disclosed in a filing with the SEC, which is available at this hyperlink. Also, Director Robert Nelsen bought 170,000 shares of the business’s stock in a transaction that occurred on Monday, October 19th. The stock was acquired at an average cost of $18.00 per share, for a total transaction of $3,060,000.00. Following the completion of the purchase, the director directly owned 13,692,507 shares of the company’s stock, valued at $246,465,126. The trade was a 1.26% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure.

About City Therapeutics

City Therapeutics is a biotechnology company developing medicines based on RNA interference (RNAi), a biological process that can reduce the production of specific disease-related proteins. Its research focuses on designing RNAi therapies for potential use across a range of diseases. Launched in 2024, the company is developing technology intended to advance the design and delivery of RNAi medicines. Its work is research and development focused; the company’s activities center on building a therapeutic pipeline rather than marketing established products.